In this cohort study, a novel prognostic model was developed to estimate prostate cancer-specific mortality (PCSM) while ...

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...

Study results are based on Surveillance, Epidemiology, and End Results-Medicare data for 166,581 patients receiving surgery or radiation for localized prostate cancer.

Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented ...

A man was given two years to live after a colon cancer diagnosis. Now he's healthy thanks to combination of medicine and the ...

ARTBIO, Inc. ("ARTBIO"), a clinical-stage radiopharmaceutical company developing a new class of 212Pb alpha radioligand therapies (ARTs), today commenced dosing of two cohorts in the U.S. as part of ...

In this analysis, researchers aimed to evaluate the clinicopathologic characteristics, metastatic patterns, and survival outcomes in patients with metastatic prostate cancer and low-volume primary ...

Mr. Green, a 50-something businessman was asking a question I find myself answering on a surprisingly regular basis: “So, my ...

The therapy is a highly advanced form of radiation therapy that uses charged particles in the form of a proton that that gets ...

Andy Gissing, 62, from Portsmouth, Hampshire, is now trying to fund privately a 'last hope' treatment - and that without it ...

About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...